Adamis Pharmaceuticals enters CEO employment agreement with Ebrahim Versi, M.D., Ph.D.

DMK PHARMACEUTICALS Corp

Base salary of $585K/year effective from May 25, 2023 merger closing; lump sum retroactive payment for prior period.
Target annual bonus of 60% of base salary; eligibility for discretionary bonuses and equity awards.
Termination without cause or for good reason yields 18 months salary continuation (or lump sum if within 12 months before/after change in control).
Change in control triggers full vesting acceleration of all stock options and RSUs.
Severance includes COBRA premium coverage for up to 18 months, subject to release.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ebrahim Versi, M.D., Ph.D.

Chief Executive Officer and Chairman of the Board

DMK PHARMACEUTICALS Corp

Effective: 2023-05-25
Filed: August 29, 2023, 7:59 PM ET

On August 23, 2023, Adamis Pharmaceuticals Corporation (the “Company”) entered into an employment agreement with Ebrahim Versi, M.D., Ph.D., who became the Company’s Chief Executive Officer and Chairman of the board of directors of the Company (the “Board”) in connection with the closing of the merger transaction (the “Merger”) with DMK Pharmaceuticals Corporation effective May 25, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ebrahim Versi, M.D., Ph.D. was appointed as Chief Executive Officer and Chairman of the Board at DMK PHARMACEUTICALS Corp.

Action: appointed
Role: Chief Executive Officer and Chairman of the Board

Exact text from the filing

On August 23, 2023, Adamis Pharmaceuticals Corporation (the “Company”) entered into an employment agreement with Ebrahim Versi, M.D., Ph.D., who became the Company’s Chief Executive Officer and Chairman of the board of directors of the Company (the “Board”) in connection with the closing of the merger transaction (the “Merger”) with DMK Pharmaceuticals Corporation effective May 25, 2023.

View on SEC.gov

Source: SEC EDGAR

accession 0001839882-23-022729

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.